title: Development of terbinafine solid lipid nanoparticles as a topical delivery system.
abstract: To resolve problems of long treatment durations and frequent administration of the antifungal agent terbinafine (TB), solid lipid nanoparticles (SLNs) with the ability to load lipophilic drugs and nanosize were developed. The SLNs were manufactured by a microemulsion technique in which glyceryl monostearate (GMS), glyceryl behenate (Compritol(®) 888; Gattefossé), and glyceryl palmitostearate (Precirol(®) ATO 5; Gattefossé) were used as the solid lipid phases, Tween(®) and Cremophor(®) series as the surfactants, and propylene glycol as the cosurfactant to construct ternary phase diagrams. The skin of nude mice was used as a barrier membrane, and penetration levels of TB of the designed formulations and a commercial product, Lamisil(®) Once™ (Novartis Pharmaceuticals), in the stratum corneum (SC), viable epidermis, and dermis were measured; particle sizes were determined as an indicator of stability. The optimal SLN system contained a <5% lipid phase and >50% water phase. The addition of ethanol or etchants had no significant effect on enhancing the amount of TB that penetrated the skin layers, but it was enhanced by increasing the percentage of the lipid phase. Furthermore, the combination of GMS and Compritol(®) 888 was able to increase the stable amount of TB that penetrated all skin layers. For the ACP1-GM1 (4% lipid phase; Compritol(®) 888: GMS of 1:1) formulation, the amount of TB that penetrated the SC was similar to that of Lamisil(®) Once™, whereas the amount of TB of the dermis was higher than that of Lamisil(®) Once™ at 12 hours, and it was almost the same as that of Lamisil(®) Once™ at 24 hours. It was concluded that the application of ACP1-GM1 for 12 hours might have an efficacy comparable to that of Lamisil(®) Once™ for 24 hours, which would resolve the practical problem of the longer administration period that is necessary for Lamisil(®) Once™.
authors.affiliation: School of Pharmacy, College of Pharmacy, Taipei Medical University Hospital, Taipei, Taiwan.
authors.forename: Ying-Chen
authors.initials: YC
authors.lastname: Chen
authors.forename: Der-Zen
authors.initials: DZ
authors.lastname: Liu
authors.forename: Jun-Jen
authors.initials: JJ
authors.lastname: Liu
authors.forename: Tsung-Wei
authors.initials: TW
authors.lastname: Chang
authors.forename: Hsiu-O
authors.initials: HO
authors.lastname: Ho
authors.forename: Ming-Thau
authors.initials: MT
authors.lastname: Sheu
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D020405:Dermis / Q000737:chemistry / Q000378:metabolism; D004304:Dosage Forms; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry; D004817:Epidermis / Q000737:chemistry / Q000378:metabolism; D005989:Glycerides / Q000008:administration & dosage / Q000737:chemistry; D007700:Kinetics; D051379:Mice; D008819:Mice, Nude; D008855:Microscopy, Electron, Scanning; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D009281:Naphthalenes / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D010316:Particle Size; D012869:Skin Absorption; D012995:Solubility; D000077291:Terbinafine
chemical_list: D000935:Antifungal Agents; D004304:Dosage Forms; D004337:Drug Carriers; D005989:Glycerides; D009281:Naphthalenes; D000077291:Terbinafine